Literature DB >> 9234336

In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera.

M Hassan1, E Refai, M Andersson, P O Schnell, H Jacobsson.   

Abstract

The in vivo distribution of vasoactive intestinal peptide (VIP) was studied for the first time using a rat model in combination with labeled VIP (131I-VIP) and a gamma-camera. A dynamic scan showed that 131I-VIP was cleared rapidly from the blood circulation. The radioactivity was taken up and accumulated in the lungs during the first minute. During the next 15 min, the radioactivity was slowly removed from the lungs and redistributed into the kidneys, gastric mucosa, liver and small intestine. However, the radioactivity extracted by the lungs was about 6-fold lower during the first minute when a large amount of the non iodinated VIP was coinjected with the 131I-VIP. 131I-VIP was eliminated rapidly from the blood with a half-life of 0.44 +/- 0.05 (min +/- SD) while in lung the elimination half-life was determined to 2.3 +/- 0.8 (min +/- SD). Of the radioactivity in the lungs, 2% was found to be intact 131I-VIP after 20 min. In all other organs the radioactivity found was assumed to be low molecular weight fragments of 131I-VIP. We suggest that lungs play an important role to extract VIP from the circulation after an i.v. administration. 131I-VIP degradation products are redistributed mostly to the kidneys and to the gastric mucosa to be excreted through urine and stomach contents, respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9234336     DOI: 10.1016/0969-8051(94)90166-x

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

1.  Homeostatic and therapeutic roles of VIP in smooth muscle function: myo-neuroimmune interactions.

Authors:  Xuan-Zheng Shi; Sushil K Sarna
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-08-06       Impact factor: 4.052

2.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

Review 3.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

4.  Gene therapy of Cav1.2 channel with VIP and VIP receptor agonists and antagonists: a novel approach to designing promotility and antimotility agents.

Authors:  Xuan-Zheng Shi; Sushil K Sarna
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-08       Impact factor: 4.052

Review 5.  PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma.

Authors:  James A Waschek; Serapio M Baca; Simon Akerman
Journal:  J Headache Pain       Date:  2018-03-13       Impact factor: 7.277

6.  Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

Authors:  Jun Yin; Liming Wang; Ning Yin; Arata Tabuchi; Hermann Kuppe; Gerhard Wolff; Wolfgang M Kuebler
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

Review 7.  PACAP38 and PAC1 receptor blockade: a new target for headache?

Authors:  Eloisa Rubio-Beltrán; Edvige Correnti; Marie Deen; Katharina Kamm; Tim Kelderman; Laura Papetti; Simone Vigneri; Antoinette MaassenVanDenBrink; Lars Edvinsson
Journal:  J Headache Pain       Date:  2018-08-07       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.